---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-26-000033"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-05-14T13:01:44+00:00"
generated_at: "2026-05-14T13:04:44.340883+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Therapeutics reports preclinical data showing CMP-002 improves seizure threshold in SYNGAP1 model

## Summary
- CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.
- Data presented at TIDES conference on May 14, 2026; builds on prior motor/behavioral benefit evidence.
- Company plans to advance CMP-002 into a Phase 1/2 clinical trial in SYNGAP1-related disorder in H2 2026.
- Lead candidate CMP-002 is an antisense oligonucleotide targeting regulatory RNA to upregulate SYNGAP1 protein.
- Study used PTZ-induced seizure model; CMP-002 conferred resistance to tonic-clonic seizures and reduced severity.

## SEC filing metadata
- accession: 0001736730-26-000033
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-05-14T13:01:44+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000033/0001736730-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000033/camp-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-26-000033
- JSON: https://secwatch.observer/filing/0001736730-26-000033.json
- Plain text: https://secwatch.observer/filing/0001736730-26-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.